Noxxon to Host Key Opinion Leader Webinar on GLORIA Study Top-line Results of NOX-A12 & Radiotherapy Combination in First-line Glioblastoma

Regulatory News:

NOXXON Pharma N.V. (Euronext Growth Paris: ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), announced today that it will host a key opinion leader (KOL) webinar on the top-line results of GLORIA on Friday, June 10, 2022, at 2:00 p.m. CEST / 08:00 a.m. EDT. GLORIA is a Phase 1/2 study of NOX-A12 and radiotherapy combination in first-line glioblastoma multiforme. The top-line data will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting.

The webinar will feature a presentation from Frank A. Giordano, M.D., Chair, Department of Radiation Oncology, University Hospital Bonn, Germany, who will present and discuss the results of the GLORIA Phase 1/2 trial evaluating NOX-A12 in combination with radiotherapy in patients with newly diagnosed glioblastoma and unmethylated MGMT promoter.

The webinar will follow Dr. Giordano’s poster presentation at the 2022 ASCO Annual Meeting that will take place from June 3-7, 2022, in Chicago, Illinois, United States. Dr. Giordano will discuss the results based on 6-month therapy of patients treated in the GLORIA study that complement the recently reported positive data.

NOX-A12 is an inhibitor of the chemokine CXCL12 and has been granted orphan drug status in the US and EU for the treatment of certain brain cancers and produced promising clinical data thus far. Dr. Giordano will be available for questions following the formal presentation.

To register for the webinar, please click here.

Dr. Frank Giordano is Director and Chair of the Department of Radiation Oncology at the University Hospital Bonn, Germany. He is an expert in precision radiation therapy and intraoperative irradiation of malignant tumors and has received international recognition for his brain tumor research, including an award from the American Society of Radiation Oncology (ASTRO) and an honorary membership of the Spanish Society of Radiation Oncology (SEOR). Dr. Giordano received his medical degree from the University of Heidelberg, Germany, and did his post-doctoral training as a Peter Engelhorn fellow at the German Cancer Research Center (DKFZ). He received clinical training at the National Center for Tumor Diseases (NCT) Heidelberg and the University Medical Center Mannheim, where he served as acting chairman and director of the Department of Radiation Oncology before moving to Bonn. For many years, his research has focused on optimized radiation therapy of brain cancers to offer cancer patients personalized and even more effective treatment. As one of the few Else-Kröner-Fresenius Excellence Fellows, Dr. Giordano developed innovative therapy options that even found their way in clinical practice. He sees great potential in the combination of radiotherapy and immunomodulatory therapy.